Since mutations in Nav1.2 are generally believed to cause epilepsy through gains of channel function, patients whose epilepsy is reasonably attributable to a SCN2A (Nav1.2) mutation are generally expected to respond well to sodium channel blockers, such as carbamazepine, phenytoin, and lamotrigine. The gene discussed is SCN2A; the disease is epilepsy.